The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

A gut-derived compound called propionate may slow the progression of Alzheimer's disease by reducing inflammation and plaque ...

The world just got a little closer. The new iGlobal Radio App is now live, offering users a dynamic way to connect with radio ...

New analysis of traffic patterns on Toronto's Gardiner Expressway reveals a harsh reality for commuters and commercial fleets alike: ongoing construction is effectively doubling travel times in key ...

A team led by Rutgers University-New Brunswick engineers has developed a portable device capable of detecting rare genetic ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...